

Special Issue

Advances in Pharmacotherapy for Nasal Disorders in Rhinology

Message from the Guest Editor

In the last decade, precision medicine and new biologics have revolutionized clinical practice. Every day we face new therapeutic challenges that require a meticulous selection process. This Special Issue aims to provide readers and colleagues with several new therapeutic strategies for the treatment of sinonasal diseases in adults and children. Chronic rhinosinusitis is a widespread and challenging disease affecting about 5% to 12% of the general population, exerting a significant social and economic impact. Chronic rhinosinusitis is characterized by chronic inflammation in the paranasal sinus, with persistent and debilitating symptoms that include nasal obstruction, hyposmia, or anosmia. Persistent symptoms have a strong negative impact on the patient's quality of life and productivity compared to other serious chronic diseases. These are the reasons that I proposed this Special Issue to collect articles on "Advances in Pharmacotherapy for Nasal Disorders in Rhinology". Studies should describe the challenges and perspectives in rhinology diagnostics and therapy using basic science, clinical, and population-based approaches.

Guest Editor

Dr. Elena Cantone

Department of Neuroscience, Reproductive and Odontostomatological Sciences-ENT Section, University of Naples "Federico II", 80131 Naples, Italy

Deadline for manuscript submissions

closed (30 September 2025)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/217830

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*.

Pharmaceuticals is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)